Clinical Trial Update: Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating eculizumab to prevent antibody-mediated rejection in ABO-incompatible living-donor kidney transplantation; the study was ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• SOLIRIS (eculizumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Kidney Transplant | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2015-06-19